Showing posts with label HIV medications. Show all posts
Showing posts with label HIV medications. Show all posts

November 12, 2013

Walgreens Studies Demonstrate Success of HIV-Specialized Pharmacies in Improving Patient Medication Adherence

PRESS RELEASE

Nov. 12, 2013, 2:56 p.m. EST

Company presents study findings at Cell-Lancet HIV/AIDS conference

DEERFIELD, Ill., Nov 12, 2013 (BUSINESS WIRE) -- Walgreens WAG -0.01% WAG -0.01% recently presented research from two retrospective cohort studies exploring HIV and comorbid medication adherence at HIV-specialized pharmacies and the implications for HIV patients with serious mental illness(1). The research, presented at the Cell-Lancet conference, What Will it Take to Achieve an AIDS-free World?, in San Francisco, demonstrates that adherence to therapeutic treatments for HIV and associated comorbidities, such as serious mental illness, was significantly higher for patients using Walgreens HIV-specialized pharmacies than for patients using other Walgreens retail pharmacies.

"Medication adherence is vital to maintaining optimal health for patients with the HIV virus. Poor medication adherence can lead to treatment failure, resistance to therapy and increased mortality and is one of the greatest and most costly barriers in treating illness today," said Janeen DuChane, PhD, senior director of clinical outcomes and analytics, Walgreens. "By developing specialized patient support programs, we can improve adherence for HIV patients, better serve HIV populations and reduce medical costs."

In examining the differences in medication adherence for patients using Walgreens HIV-specialized pharmacies and those using other Walgreens retail pharmacies, researchers confirmed that HIV patients utilizing the specialized pharmacies were more adherent to their anti-retroviral and comorbid therapies. The study found that the mean proportion of days covered for patients using Walgreens HIV-specialized pharmacies was significantly higher than for patients using other Walgreens retail pharmacies.

-- For patients taking angiotensin converting enzyme or angiotensin receptor blocker (drugs used to treat hypertension), Walgreens HIV-specialized pharmacy users had a significantly higher mean proportion of days covered of 82.6 percent compared with 79.6 percent in patients using other Walgreens retail pharmacies.

-- Among patients taking statins (drugs used to treat high cholesterol), Walgreens HIV-specialized pharmacy users also had a higher mean proportion of days covered of 83.7 percent than those using other Walgreens retail pharmacies (81.3 percent).

In a separate study, Walgreens researchers conducted a retrospective data analysis of HIV patients with serious mental illness, a group that often experience challenges associated with the willingness and ability to take medication as prescribed which can contribute to a two-fold increase in hospitalization costs. Nearly 30 percent of HIV patients assessed had an indication of serious mental illness comorbidity and demonstrated increased medication adherence(2) when utilizing a Walgreens HIV-specialized pharmacy. Specifically, the study found:

-- Among HIV patients with serious mental illness who exclusively used HIV-specialized pharmacies, 32.7 percent were adherent to their anti-retroviral therapy versus 19.4 percent for HIV patients with serious mental illness using other Walgreens retail pharmacies.

Both studies validate the benefit of patient medication adherence associated with HIV-specialized pharmacies and underscore Walgreens commitment to be a part of the solution to end AIDS. Walgreens award-winning HIV-specialized pharmacies provide education, counseling, testing and treatment through its more than 2,000 HIV-trained pharmacists at more than 700 locations.

The Cell-Lancet conference, What Will it Take to Achieve an AIDS-free World?, gathered both research and medical experts to share and discuss the latest developments in the fight against HIV/AIDS.

About Walgreens

As the nation's largest drugstore chain with fiscal 2013 sales of $72 billion, Walgreens (www.walgreens.com) vision is to be the first choice in health and daily living for everyone in America, and beyond. Each day, Walgreens provides more than 6 million customers the most convenient, multichannel access to consumer goods and services and trusted, cost-effective pharmacy, health and wellness services and advice in communities across America. Walgreens scope of pharmacy services includes retail, specialty, infusion, medical facility and mail service, along with respiratory services. These services improve health outcomes and lower costs for payers including employers, managed care organizations, health systems, pharmacy benefit managers and the public sector. The company operates 8,131 drugstores in all 50 states, the District of Columbia, Puerto Rico and the U.S. Virgin Islands. Take Care Health Systems is a Walgreens subsidiary that is the largest and most comprehensive manager of worksite health and wellness centers and in-store convenient care clinics, with more than 750 locations throughout the country.

Source

October 28, 2013

HIV drugs may get new role in fighting cancer

r

By Ben Hirschler

Fri Oct 25, 2013 3:07pm EDT

(Reuters) - A type of HIV medicine that stops the AIDS virus from entering immune system cells could in future be put to work against cancer in new combination therapies being developed by drug companies.

Interest in using so-called CCR5 inhibitors to fight tumors was fuelled last year when U.S. researchers, testing the drugs on mice, reported a marked reduction in aggressive breast cancer cells spreading to the animals' lungs.

Researchers from the Thomas Jefferson University Kimmel Cancer Center described the results as "dramatic" after they were published in the Journal of Cancer Research.

Now industry analysts at Citi believe Merck & Co Inc is set to take things to the next stage by testing its CCR5 drug vicriviroc in cancer patients. The product was abandoned as a treatment for HIV in 2010 following an unsuccessful study.

Pfizer Inc and Bristol-Myers Squibb - which also have similar drugs in their portfolios - could follow suit, Citi said in a note on Friday.

Asked to comment on the suggestion that it would start testing vicriviroc in patients in 2014 as part of a combination therapy for cancer, a spokesman for Merck said: "We have not disclosed any such plans."

Citi said it expected vicriviroc to re-enter clinical testing in combination with cancer immunotherapy as Merck explores its potential across multiple tumor types, including melanoma, colorectal, breast, prostate and liver cancer.

Immunotherapy, which harnesses the body's immune system to fight cancer, is a hot new area for cancer research, with some experts predicting the approach will in future form the backbone of many cancer treatments.

However, drug combinations are expected to be critical to its success as oncologists will need to block cancer cells on several fronts at once.

One option is to combine two immunotherapies, while another approach, also being pursued by other companies like Roche Holding AG and AstraZeneca Plc, is to combine immunotherapy medicines with different drug types.

CCR5 inhibitors are one such option, given the encouraging signals from pre-clinical research. As these drugs have already been studied in HIV, their development could be relatively rapid.

Pfizer could also start clinical trials in cancer with its approved CCR5 drug Selzentry, which is currently marketed for HIV via the ViiV Healthcare alliance with GlaxoSmithKline Plc and Shionogi & Co Ltd.

Bristol, meanwhile, has a dual CCR2/5 inhibitor in mid-stage Phase II development, which is being tested for diabetes and kidney disease.

(Editing by Patrick Lannin)

Source